The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Targeting fibroblast activation protein in cancer ndash Prospects and caveats
Abstract
Fibroblast activation protein (FAP, seprase) is a serine protease with post-proline dipeptidyl peptidase and endopeptidase enzymatic activity. FAP is upregulated in several tumor types, while its expression in healthy adult tissues is scarce. FAP molecule itself and FAP+ stromal cells play an important although probably context-dependent and tumor type-specific pathogenetic role in tumor progression. We provide an overview of FAP expression under both physiological and pathological conditions with focus on human malignancies. We also review and critically analyze the results of studies which used various strategies for the therapeutic targeting of FAP including the use of low molecular weight inhibitors, FAP activated prodrugs, anti-FAP antibodies and their conjugates, FAP-CAR T cells, and FAP vaccines. A unique enzymatic activity and selective expression in tumor microenvironment make FAP a promising therapeutic target. A better understanding of its role in individual tumor types, careful selection of patients, and identification of suitable combinations with currently available anticancer treatments will be critical for a successful translation of preclinically tested approaches of FAP targeting into clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100 · cited 5×
“FAP-expressing cells are an important source of immunosuppressive molecules such as heme oxygenase 1, prostaglandin E synthase, CXCL12, and CCL2 (82, 122, 124-126).”
BackgroundInfluentialSpaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Yang, X., Lin, Y., Shi, Y., Li, B., Liu, W., Yin, W., Dang, Y., Chu, Y., Fan, J., & He, R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2973 · Cited by 748
Loeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633 · cited 3×
“Especially in highly desmoplastic tumors, FAP targeting may also improve the efficacy of conventional cytostatic agents by increasing their penetration into the tumor tissue (219) and reducing CAF functions (178).”
BackgroundKidd, S., Spaeth, E., Watson, K., Burks, J., Lu, H., Klopp, A., Andreeff, M., & Marini, F. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030563 · Cited by 371 · cited 1×
“To conclude, the frequently observed upregulation of FAP in cancer tissue seems to be the result of a complex paracrine and/or juxtacrine communication between the transformed cells and their microenvironment, of the recruitment of bone marrow-derived mesenchymal stem cells (174), and of an activation of the epithelia…”
BackgroundAcharya, P. S., Zukas, A., Chandan, V., Katzenstein, A.-L. A., & Puré, E. (2006) · Human Pathology · doi:10.1016/j.humpath.2005.11.020 · Cited by 204 · cited 2×
“Patients with liver fibrosis/cirrhosis (60), advanced atherosclerosis (59), Crohn’s disease (58), idiopathic pulmonary fibrosis (63), recent myocardial infarction (57), keloids, scleroderma (56), or rheumatoid arthritis (64) should not be involved in trials with anticancer FAP treatments.”
BackgroundFibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21
Dunshee, D. R., Bainbridge, T. W., Kljavin, N. M., Zavala-Solorio, J., Schroeder, A. C., Chan, R., Corpuz, R., Wong, M., Zhou, W., Deshmukh, G., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.710582 · Cited by 158 · cited 1×
“Substrates which are cleaved in vivo include human fibroblast growth factor 21 (FGF-21), a protein involved in the regulation of energy metabolism and insulin sensitivity (26-28), human alpha2 antiplasmin (9), and probably also collagen I (24) (Figure 1).”
BackgroundCirculating FGF21 proteolytic processing mediated by fibroblast activation protein
Zhen, E. Y., Jin, Z., Ackermann, B. L., Thomas, M. K., & Gutierrez, J. A. (2016) · Biochemical Journal · doi:10.1042/bj20151085 · Cited by 123 · cited 1×
“Substrates which are cleaved in vivo include human fibroblast growth factor 21 (FGF-21), a protein involved in the regulation of energy metabolism and insulin sensitivity (26-28), human alpha2 antiplasmin (9), and probably also collagen I (24) (Figure 1).”
Background
Cited by
Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
Loktev, A., Lindner, T., Burger, E.-M., Altmann, A., Giesel, F., Kratochwil, C., Debus, J., Marmé, F., Jäger, D., Mier, W., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224469 · Cited by 554
The Latest Developments in Imaging of Fibroblast Activation Protein
Altmann, A., Haberkorn, U., & Siveke, J. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.244806 · Cited by 257
Xin, L., Gao, J., Zheng, Z., Chen, Y., Lv, S., Zhao, Z., Yu, C., Yang, X., & Zhang, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648187 · Cited by 203
Targeted antibody and cytokine cancer immunotherapies through collagen affinity
Ishihara, J., Ishihara, A., Sasaki, K., Lee, S. S.-Y., Williford, J.-M., Yasui, M., Abe, H., Potin, L., Hosseinchi, P., Fukunaga, K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau3259 · Cited by 190
AND-gate contrast agents for enhanced fluorescence-guided surgery
Widen, J. C., Tholen, M., Yim, J. J., Antaris, A., Casey, K. M., Rogalla, S., Klaassen, A., Sorger, J., & Bogyo, M. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00616-6 · Cited by 142
Metadata
- Authors
- Sedo, A.
- Venue
- Frontiers in Bioscience
- Publisher
- IMR Press
- Published
- 2018
- Volume
- 23
- Issue
- 10
- Pages
- 1933-1968
- ISSN
- 1093-4715 (ISSN-L)
- 1093-9946
- DOI
- 10.2741/4682
- OpenAlex
- W2803334969
- Cited by
- 161
- References
- 9
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting fibroblast activation protein in cancer ndash Prospects and caveats. https://app.cochat.ai/papers/10.2741/4682
- The paper
- Sedo, A. (2018). Targeting fibroblast activation protein in cancer ndash Prospects and caveats. Frontiers in Bioscience. https://doi.org/10.2741/4682
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.